Arcutis will receive $30M up front, ~$64.25M upon achievement in regulatory & sales milestones along with royalties & lead the development & commercialization of Zoryve in the US & other geographies
Huadong to get an exclusive license for cream & foam formulations of roflumilast (PDE4) inhibitor for multiple dermatological conditions incl. PsO, seborrheic dermatitis, AD & additional dermatological conditions in the future
Huadong will lead the development, manufacturing & commercialization of roflumilast (0.3%) and other topical roflumilast in Greater China and Southeast Asia with the oversight of a joint steering committee comprised of individuals from both companies. Roflumilast was approved in the US for PsO in adults & adolescents
Ref: Arcutis | Image: Arcutis
Related News:- Arcutis Reports the US FDA Acceptance of NDA for Roflumilast to Treat Seborrheic Dermatitis in Individuals Aged ≥9 Years
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
